ANVS Stock ANVS is expected to report earnings to rise+63% to -84 cents per share on May 13

A.I.dvisor
at Tickeron.com
05/12/24
Loading...
ANVS - Annovis Bio
Annovis Bio Earnings Graph
Q1'24
Est.
$-0.84
Q4'23
Missed
by $0.82
Q3'23
Missed
by $0.54
Q2'23
Beat
by $0.07
Q1'23
Missed
by $0.60
The last earnings report on December 31 showed earnings per share of -224 cents, missing the estimate of -142 cents. P/B Ratio (0.000) is normal, around the industry mean (10.609). P/E Ratio (0.000) is within average values for comparable stocks, (160.883). ANVS's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.422). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (236.959). With 529.48K shares outstanding, the current market capitalization sits at 65.36M.
View a ticker or compare two or three
ANVSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
101 Lindenwood Drive
Phone
+1 484 875-3192
Employees
6
Web
https://www.annovisbio.com